Rubicon Research Limited (NSE:RUBICON)

Market Cap	107.10B
Revenue (ttm)	14.36B
Net Income (ttm)	1.71B
Shares Out	164.75M
EPS (ttm)	11.05
PE Ratio	58.81
Forward PE	40.31
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,983
Average Volume	173,622
Open	664.00
Previous Close	664.60
Day's Range	644.25 - 664.00
52-Week Range	570.75 - 754.80
Beta	n/a
RSI	44.79
Earnings Date	Feb 12, 2026

About Rubicon Research

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, ...

• Industry: Pharmaceutical Preparations
• Founded: 1999
• Employees: 903
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: RUBICON

Financial Performance

In 2024, Rubicon Research's revenue was 12.84 billion, an increase of 50.40% compared to the previous year's 8.54 billion. Earnings were 1.34 billion, an increase of 47.63%.